A Safer CAR T Therapy Is Coming

1. www.creative-biolabs.com/car-t A Safer CAR T Therapy Is Coming

2. Part 1 Introduction

3. Introduction Two heavy CAR-T therapies have been approved in 2017. Although this revolutionary therapy has brought hope to patients for treatment that was once unattainable, there are still some problems that need to be solved, such as recurrence of disease, therapeutic toxicity, and specific killing. To solve these problems, Dr. Wilson Wong of Boston University and his team designed a new type of CAR-T therapy, which is expected to become the 2.0 version of CAR-T therapy.

4. Introduction Two heavy CAR-T therapies have been approved in 2017. Although this revolutionary therapy has brought hope to patients for treatment that was once unattainable, there are still some problems that need to be solved, such as recurrence of disease, therapeutic toxicity, and specific killing. To solve these problems, Dr. Wilson Wong of Boston University and his team designed a new type of CAR-T therapy, which is expected to become the 2.0 version of CAR-T therapy.

5. Introduction Two heavy CAR-T therapies have been approved in 2017. Although this revolutionary therapy has brought hope to patients for treatment that was once unattainable, there are still some problems that need to be solved, such as recurrence of disease, therapeutic toxicity, and specific killing. To solve these problems, Dr. Wilson Wong of Boston University and his team designed a new type of CAR-T therapy, which is expected to become the 2.0 version of CAR-T therapy.

6. Part 2 Current Situation

7. Introduction At present, the CAR-T therapy is based on the following procedures: T cells are collected from the patient's blood, and then the chimeric antigen receptors (CARs) are expressed on the surface by genetic engineering. After the new engineered CAR-T cells are expanded in the laboratory Then re-injected into the patient to specifically attack the tumor. However, Dr. Wong believes that the biggest limitation of the current CAR-T therapy is that the receptor is a fixed molecule. After the CAR design has been expressed by T cells, it cannot be changed. These transformed T cells can only be allowed to function after they have been infused into patients. If everything goes as it pleases, but if it's counterproductive, a dangerous side effect may occur -- the cytokine release syndrome. Cancer cells may also no longer express the recognized antigen through the escape process of antigens, thereby avoiding the tracing of CAR-T cells and causing cancer recurrence.

8. Part 3 How to Improve

9. Introduction To improve these limitations of CAR-T therapies, such as narrow applications, lack of flexibility, and uncontrollable intensity, Dr. Wong's team created a separate, universal, and editable (SUPRA) CAR system. Instead of relying on a single fixed CAR, the CAR T technology separates it into two-component receptor systems: the universal receptor zipCARs expressed on T cells, and the adaptor molecules zipFv, which carries specific antigen antibodies that can identify cancer cells. The two components are pulled through the leucine zipper to guide engineered T cells to seek and destroy cancer cells. The core part of this technology is that the retrofitted CAR-T was established for the two markers of disease, greatly improving the chance of using this therapy for refractory solid tumors, and at the same time improving the therapy for tumors. The specificity of the organization. It is also a customizable therapy with better built-in regulation that can be used to treat specific types of hematological cancers and solid tumors.

10. Another key part of this technology is the addition of adaptor molecules that can guide T cells to recognize cancer cells during therapy. Without these adaptors, T cells will not be activated. When they are finally cleared, a batch of adapter molecules can be added to respond to the new target. This is like an “on/off” device that can fine-tune the activity of the treatment to control toxicity and prevent over-activation of the patient with dangerous side effects, and it can also more easily stimulate subsequent reactions to prevent recurrence.

11. Subsequently, Dr. Wong's team tested this new CAR T service in a mouse model. Mice that were injected with Her2 positive breast cancer cells received a dose of zipCAR-T cells and received appropriate adapter molecules on alternate days for two weeks. The results show that SUPRA CAR therapy shows a similar tumor burden clearance rate as conventional CAR-T therapy. In a hematological cancer model, mice received daily injections of adaptor molecules for six days after receiving engineered T cells and similar results were obtained, demonstrating that the SUPRA CAR system addresses the potential of many different cancer types. “Our top priority is to figure out which types of cancer will really benefit from such combination targeting and regulation,” said Dr. Wong. This may include cancers with very high heterogeneity because they do not have good single markers. Therefore, the subsequent work will be a major and major challenge. "Every cancer may need to fine-tune the adapters," Dr. Wong added.

12. About Creative Biolabs As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

13. Contact us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

14. www.creative-biolabs.com/car-t A Safer CAR T Therapy Is Coming